



**IAS-Industry Consultation on the Integration of HIV and Other Diseases:
From Single Disease to Complete Patient Management**

Tuesday, 21 July 2015, 18:00 – 21:30 PST / Room 306, Vancouver Convention Centre, Vancouver, Canada

CONCEPT NOTE

The increasing importance to strengthen health systems with integrated and coordinated approaches for HIV and other diseases is at the forefront of new objectives. Primary focus has been set upon the existing, but often “silent” tuberculosis (TB) integration, viral hepatitis, and the emerging recognition of the increased burden in low and middle-income countries of non-communicable diseases (NCDs). These diseases often greatly affect PLHIV and their communities. Lessons learned from the HIV response are critical in reaching integration and strengthening of health systems in a sustainable manner. However, integration approaches must carefully assess the risks and benefits to existing structures, and consider all of the relevant stakeholders in implementation.

The International AIDS Society (IAS)-Industry Consultation Series allows for strategic, high-level discussions between the IAS (Staff and Governing Council) and industry; this is an invaluable opportunity for industry, the IAS, and the global response to HIV. For IAS 2015, the IAS’s Industry Liaison Forum (ILF) has chosen to focus the IAS-Industry Consultation on the topic of integration of responses for HIV and other diseases (in particular TB, viral hepatitis and NCDs).

This *IAS-Industry Consultation on the Integration of HIV and Other Diseases: From Single Disease to Complete Patient Management* will provide a platform for participants to meet and discuss the challenges and opportunities to “bridge the gap” of integrated approaches, and health system strengthening between HIV and TB, viral hepatitis and NCDs. A keynote presentation will set the stage and frame health system strengthening and integration from the HIV perspective, while an open, roundtable discussion will allow all participants to contribute to the exchange of ideas. The discussion will cover issues around (1) Ongoing integration of HIV and TB: Is it working? (2) Upcoming integration of HIV and viral hepatitis: Are systems strong enough to cater for this integration? (3) Foreseen integration of HIV and NCDs: Will low and middle-income countries be ready? This will include considerations on the impact of the flow of financing on product research and development and the overall integration of the response to multiple diseases.

The main objectives for this meeting are to:

- Raise awareness among participants of challenges and opportunities for health system integration, particularly around HIV and including the industry perspective
- Identify key recommendations for building from the HIV response to contribute to progress for other diseases and to health in general
- Catalyze collaboration among attendees from different types of organizations.

Thank you for your interest.

Kenneth Mayer, MD
ILF Co-Chair
Fenway Institute, USA

Manuel Gonçalves, MD
ILF Co-Chair
ViiV Healthcare, UK

Sébastien Morin, PhD
ILF Research Officer
International AIDS Society, Switzerland



About the International AIDS Society

Founded in 1988, the International AIDS Society (IAS) is the world's largest association of HIV professionals, with members from more than 180 countries. IAS members work on all fronts of the global response to AIDS, and include researchers, clinicians, policy and programme planners and public health and community practitioners on the frontlines of the epidemic.

The IAS organizes the world's two most prestigious HIV conferences, each convened biennially in alternating years. The International AIDS Conference is the largest conference on any global health or development issue, and provides a unique forum for the intersection of science and advocacy. The IAS Conference on Pathogenesis, Treatment and Prevention brings together a broad cross section of HIV professionals and features the latest HIV science, with a focus on implementation – moving scientific advances into practice.

In addition, the IAS advocates for urgent action to reduce the global impact of HIV, including increased investment in HIV cure research; optimizing treatment and care for infants, children and adolescents with HIV in resource-limited settings; preventing and treating HIV-related co-infections; and expanding access to prevention, treatment and care for key populations at higher risk for HIV – such as men who have sex with men, people who inject drugs, sex workers and transgender individuals – including protecting their human rights by combatting punitive laws and discriminatory policies.

More information is available on the IAS website (www.iasociety.org).

About the Industry Liaison Forum

The ILF is a mechanism to constructively engage all stakeholders (industry and others) on issues in line with IAS Member Priorities. It is designed to take advantage of the IAS's key strengths: its well-respected convening power; its acknowledged independence from industry and other key partners and stakeholders; and its diverse working groups composed of some of the world's top thought leaders and scientific experts in a wide array of fields. This work is guided by a strong, multi-stakeholder advisory group; it aims to enhance the impact of the global response to HIV and related co-morbidities.

More information is available on the ILF website (www.iasociety.org/ilf).

The ILF is grateful for the unrestricted support received from its Gold Partners (Gilead Sciences, MSD and ViiV Healthcare), its Silver Partners (AbbVie, Alere and Janssen) and its Bronze Partners (Abbott, Cipla, Female Health Company, Omega Diagnostics, Roche Molecular Systems and Sysmex Corporation). The ILF Thematic Roundtable Series is sponsored by ILF Gold and Silver Partners.